SANGAMO THERAPEUTICS INC
SGMO
SGMO was delisted on the 4th of May, 2026.
145 hedge funds and large institutions have $869M invested in SANGAMO THERAPEUTICS INC in 2014 Q1 according to their latest regulatory filings, with 39 funds opening new positions, 51 increasing their positions, 39 reducing their positions, and 9 closing their positions.
885% more call options, than puts
Call options by funds: $250M | Put options by funds: $25.4M
333% more first-time investments, than exits
New positions opened: 39 | Existing positions closed: 9
35% more capital invested
Capital invested by funds: $642M → $869M (+$227M)
31% more repeat investments, than reductions
Existing positions increased: 51 | Existing positions reduced: 39
26% more funds holding
Funds holding: 115 → 145 (+30)
40% less funds holding in top 10
Funds holding in top 10: 5 → 3 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$35M |
| 2 |
FCM
Frontier Capital Management
Boston,
Massachusetts
|
+$25.4M |
| 3 |
Franklin Resources
San Mateo,
California
|
+$21.1M |
| 4 |
Invesco
Atlanta,
Georgia
|
+$15.8M |
| 5 |
PA
Perceptive Advisors
New York
|
+$15.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AWMDMG
Austin W. Marxe & David M. Greenhouse
New York
|
-$24M |
| 2 |
Goldman Sachs
New York
|
-$21.6M |
| 3 |
PCA
Private Capital Advisors
Darien,
Connecticut
|
-$14.7M |
| 4 |
Adage Capital Partners
Boston,
Massachusetts
|
-$14.5M |
| 5 |
SCA
SAC Capital Advisors
Stamford,
Connecticut
|
-$11.8M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
BA
151
Bridgewater Advisors
New York
| – | -$191K | -13,780 | Closed |
|
|
PCM
152
Prelude Capital Management
New York
| – | -$38K | -2,700 | Closed |
|
153
BNP Paribas Financial Markets
Paris,
France
| – | -$11K | -790 | Closed |
|
SGMO Hedge Fund Activity: Q1 2014 in Review
145 of the 3,464 institutional investors tracked by Wall St. Rank reported a position in SANGAMO THERAPEUTICS INC (SGMO) for Q1 2014, worth a combined $869M — up 35% from $642M a quarter earlier.
Buyers outnumbered sellers: 39 funds opened new SGMO positions and 9 closed out — a net gain of 30 holders — while 51 added to existing stakes and 39 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $35M. The largest seller was Austin W. Marxe & David M. Greenhouse, cutting an estimated $24M.
- 145 institutional investors held SANGAMO THERAPEUTICS INC (SGMO) as of Q1 2014, up from 115 in Q4 2013.
- Funds reported $869M of SANGAMO THERAPEUTICS INC stock for Q1 2014, up 35% quarter-over-quarter.
- 39 funds opened new SANGAMO THERAPEUTICS INC positions in Q1 2014 and 9 closed out, a net change of +30 holders.
- The largest SANGAMO THERAPEUTICS INC buyer in Q1 2014 was Fidelity Investments, an estimated $35M added.
- The largest SANGAMO THERAPEUTICS INC seller in Q1 2014 was Austin W. Marxe & David M. Greenhouse, an estimated $24M sold.
Based on aggregated 13F filings for Q1 2014.